The product information of all chloroquine and hydroxychloroquine-containing medicines marketed in the EU will have to be updated to warn about the risk of psychiatric disorders and suicidal behavior.
Changes to the product labeling of these medicines were recommended by the EMA’s pharmacovigilance committee, the PRAC late last...